Marksans Pharma Limited has received approval from the Australian Therapeutic Goods Administration (TGA) for its state-of-the-art manufacturing facility in Verna, Goa. This approval allows the company to manufacture pharmaceutical formulations in solid dosage forms, including tablets and hard capsules, for the Australian market.
The Goa facility, located at Plot A-1, Phase 1-A, Verna Industrial Estate, will play a crucial role in expanding Marksans Pharma’s global footprint. The products manufactured here will be marketed and distributed in Australia through its wholly-owned subsidiary, Nova Pharmaceuticals Australasia Pty Ltd.
This milestone strengthens Marksans Pharma’s commitment to delivering high-quality, affordable medicines worldwide. The TGA approval enhances the company’s regulatory credentials and positions it for further growth in international markets.
In the meantime, Marksans Pharma shares opened today at ₹211.00, reaching a high of ₹215.60 and a low of ₹207.81 during the session. The stock remains significantly below its 52-week high of ₹358.70 but well above its 52-week low of ₹130.00.
